Exercise of Warrants

RNS Number : 1844V

Allergy Therapeutics PLC

06 July 2009

 



6 July 2009

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Exercise of Warrants

Allergy Therapeutics (AIM:AGY) announces that on 2 July 2009, Azure Ventures Limited partially exercised the warrant to subscribe for ordinary shares in the Company issued to it on 1 July 2009. The exercise was in respect of 12,500,000 new ordinary shares (the "Ordinary Shares") at an exercise price of 12 pence per share for a total consideration of £1.5M. 

Application has been made for the admission to trading on AIM ("Admission") of 12,500,000 Ordinary Shares at nominal value with Admission expected to take place on 10 July 2009. 

After Admission, Azure Ventures Limited will be interested in 116,666,666 Ordinary Shares, representing 42.19 per cent. of the Company's total voting rights after Admission.

After Admission, the Company's issued share capital will consist of 276,498,551 ordinary shares.

 For further information

Allergy Therapeutics Ian Postlethwaite, Finance Director	[phone]
Nomura Code Securities Juliet Thompson/ Clare Terlouw	[phone]
Financial Dynamics Ben Brewerton/ Sue Quigley	[phone]

About Allergy Therapeutics

Allergy Therapeutics plc is a London Stock Exchange (AIM) listed, integrated specialist pharmaceutical company focused on allergy vaccination. It has a growing, profitable core business achieving sales of allergy vaccines of £31 million in Germany, Italy, Spain and other EU markets through its own sales and marketing infrastructure. The Company is expanding its infrastructure with operations also in the United Kingdom, Poland, the Czech Republic, Slovakia and Austria.

 

END

 

 

MSCRFMTTMMJMBML